Skip to main content
MHRA logo
Clinical Practice Research Datalink
UK data driving real-world evidence
  • Home
    • Senior management team
    • Job vacancies
  • News
  • Public
    • Safeguarding patient data
    • CPRD case studies
    • Approved studies
    • Data use audits
    • Data protection notice
  • Data
    • Primary care data
    • Linked data
    • Synthetic data
    • Data highlights
    • DOIs
    • Research applications
      • Data access
      • Review committees
  • Our services
    • Interventional studies
      • CPRD SPRINT
      • CPRD PROVE
    • Observational research
      • CPRD-enabled research
    • Pricing
  • General Practitioner
    • GP practice joining form
    • Quality improvement reports for GPs
    • Safeguarding patient data
    • How your data makes a difference
    • What we do with information about you
  • Research
    • Approved studies
    • Bibliography
  • Log in
    • Resource modules
      • Introduction to CPRD
      • Using CPRD primary care data
      • Using linked data
      • How to access CPRD data
      • Defining your study population
      • For MSL holders

Breadcrumb

  1. Home

Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease

Author
I. Idris
R. Zhang
J. Mamza
M. Ford
T. Morris
A. Banerjee
K. Khunti
Keywords
*Cardiovascular Diseases/epidemiology/prevention & control
*Diabetes Mellitus, Type 2/complications/drug therapy
*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Glucose
*Heart Failure/epidemiology
Hospitalization
Humans
*Myocardial Infarction
Primary health care
*Renal Insufficiency, Chronic/complications/epidemiology
Retrospective Studies
Sodium
*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
*Symporters
United Kingdom/epidemiology
Cardiovascular disease
clinical trial
dapagliflozin
diabetes complications
dipeptidyl peptidase-4 inhibitor
heart failure
Year of Publication
2021
Journal
Diabetes Obes Metab
Volume
23
Number of Pages
2207-2214
ISBN Number
1462-8902 (Print)1462-8902
Accession Number
33973690
DOI
10.1111/dom.14437
  • DOI
  • Google Scholar
  • BibTeX
  • EndNote X3 XML
  • EndNote 7 XML
  • Endnote tagged
  • Marc
  • RIS

Stethoscope

GP practices - Join today

Safety studies logo

Researcher log in

stick people holding hands

Research applications

LinkedIn
Twitter
Youtube
NIHR logo

Support links

  • Accessibility statement
  • Contact
  • Privacy notice
  • Terms and conditions
  • Login
Crown Copyright © 2023 | All Rights Reserved